Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have generated a crystal structure for human PD-1 in complex with one of its ligands, PD-L2, for use in small molecule inhibitor design.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford researchers have proposed antibody-based reduction of Neuromedin (NMU) signaling as a therapeutic strategy to improve glucose metabolism in multiple physiological or disease states, including obesity, diabetes, and cancer where NMU levels are elevated.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Stanford researchers have developed a new on-chip system for laser microdissection that enables more reliable isolation of single cells or small regions of tissue and permits long-term sample storage.
Researchers at Stanford and the Chan Zuckerberg Biohub have discovered cross reactive, broadly neutralizing human antibodies against all serotypes of dengue virus.
Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.
Researchers at Stanford have developed fusion proteins, containing ACE2 domain linked to a fragment of non-neutralizing anti-SARS-CoV-2 spike protein antibody, with a greater breadth of protection than previously described similar fusion proteins.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.